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AbstrACt
Introduction Chronic Obstructive Pulmonary Disease 
(COPD)and asthma affect more than 10% of the 
population. Most patients use their inhaler incorrectly, 
mainly the elderly, thereby becoming more susceptible to 
poor clinical control and exacerbations. Placebo device 
training is regarded as one of the best teaching methods, 
but there is scarce evidence to support it as the most 
effective one to improve major clinical outcomes. Our 
objective is to perform a single-blinded RCT to assess the 
impact of this education tool in these patients.
Methods and analysis A multicentre single-blinded 
Randomised Controlled Trial (RCT) will be set up, 
comparing an inhaler education programme with a teach-
to-goal placebo-device training versus usual care, with a 
1-year follow-up, in patients above 65 years of age with 
asthma or COPD. Intervention will be provided at baseline, 
and after 3 and 6 months, with interim analysis at an 
intermediate time point. Exacerbation rates were set as 
primary outcomes, and quality of life, adherence rates, 
clinical control and respiratory function were chosen as 
secondary outcomes. A sample size of 146 participants 
(73 in each arm) was estimated as adequate to detect a 
50% reduction in event rates. Two-sample proportions χ² 
test will be used to study primary outcome and subgroup 
analysis will be carried out according to major baseline 
characteristics.
Ethics and dissemination Every participant will sign 
a written consent form. A Data Safety Monitoring Board 
will be set up to evaluate data throughout the study 
and to monitor early stopping criteria. Identity of all 
participants will be protected. This protocol was approved 
on 22 November 2017 by the local Ethics Committee of 
University of Beira Interior, with the reference number CE-
UBI-Pj-2017–025. Results will be presented in scientific 
meetings and published in peer-reviewed journals.
trial registration number NCT03449316; Pre-Results.
IntroduCtIon 
Epidemiology
Asthma and COPD affect about 10% of the 
population, but many patients have uncon-
trolled symptoms.1 In asthma, in particular, 
it should be highlighted that only 57% of all 
patients were shown to have their symptoms 
controlled,2 3 and the elderly population is 
particularly vulnerable to this condition.3 
In fact, late onset asthma may be frequently 
misdiagnosed and mistreated, and the risk of 
drug interactions also requires close moni-
toring.4 Hospitalisation rates due to asthma 
and COPD are reported to reach 27% among 
non-adherent patients and could be up to 
53% in community treated cases, and this may 
be even more apparent in elderly patients. It 
should also be stressed that good adherence 
to inhaler treatment may, in contrast, be asso-
ciated with a lower rate of severe exacerba-
tions, with reductions observed in up to half 
of the cases.5–7 
Inhaler technique
Inhaled therapy is the most widely used way 
to treat patients with asthma and COPD,8 but 
up to 90% of them do not use their inhalers 
correctly.9 10 Performance errors have been 
strengths and limitations of this study
 ► This study is innovative because it includes exclu-
sively elderly patients with asthma or COPD, ad-
dressing, in a 1-year follow-up, a specific placebo 
device education programme, alone, without any 
other aspects.
 ► No previous study has addressed this teaching 
method in these patients, as it seems to be the most 
efficient one.
 ► Our study has a randomised design, which has been 
a major limitation in previous studies.
 ► The 1-year follow-up period, with one interim evalu-
ation, allows this study to comprehensively address 
the real impact of a regular education programme.
 ► The main limitation of this study is the single blinded 
design, due to the nature of intervention itself, which 
may introduce some performance bias.
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described with almost every type of device, and over the 
past decades this problem has not improved, which high-
lights the need to better understand the specificities of 
different inhaler use as well as the impact of different 
inhaler teaching methods.11 Several inhaler devices 
are available on the market and it seems that differ-
ences either in device type or in patient characteristics 
may significantly influence performance.12 However, all 
inhalers, when properly used, show no significant differ-
ences in terms of treatment efficacy,13 14 but it is well estab-
lished that poor inhaler technique leads to poor clinical 
control15 16 and also to increased health costs.17 In addi-
tion, some type of specific errors seem to have a higher 
impact on clinical control, but there is no consensus yet 
on which errors are critical and non-critical.18 19
Patients in controlled trials receive more training in 
inhaler performance and more counselling on adher-
ence than patients who are seen as part of routine clinical 
practice, but few studies have addressed these variables 
as separate outcomes.20 Some studies show that teaching 
inhaler technique may lower the risk of exacerbations 
and death.6 21 22 However, its impact is quickly lost as 
time elapses, suggesting this is a practice that should be 
rechecked and regularly applied to patients.23 24 Never-
theless, how often the review should be carried out has 
not been established yet, since most studies have not 
addressed this issue in an isolated manner.
Significant evidence has shown that inhaler technique 
performance is regarded as particularly complex by older 
patients.25 26 These patients also present lower adherence 
rates9 and are more resistant to correct performance.27 28 
Furthermore, other major characteristics may influence 
inhaler use, such as educational level, previous teaching 
or even age itself (ie, age above 75 years).29 However, 
the significance of these observations still has to be 
fully ascertained since elderly patients are frequently 
excluded from major clinical trials. Randomised studies 
with elderly patients are scarce, and most of them did not 
address these aspects. Some of these studies have shown 
significant reductions in exacerbation risk, but most of 
them addressed several aspects of intervention besides 
inhaler technique education itself, namely self-manage-
ment plans, disease knowledge, management of exacer-
bations and their triggers. None has yet addressed inhaler 
review alone or in a regular education programme.21 30–33
Inhaler technique may be taught using many tools, 
such as step-by-step flyer schemes, video demonstrations, 
videoconferencing and face-to-face demonstrations or 
even using web-based platforms, but there is insufficient 
evidence about which is the best education method to 
improve inhaler performance or its impact on major 
outcomes.34–37 Nevertheless, some studies including 
adult patients as well suggest that the most efficient 
method seems to be using a teach-to-goal approach with 
placebo device demonstration and training provided in 
person.38–42 In addition, manufacturers’ recommenda-
tions often differ from clinical guidelines, which makes it 
difficult for patients to fully understand all the necessary 
steps of inhaler use.43 This highlights the importance 
of watching patients using their inhalers, which can be 
achieved with a placebo device training set.
This study will focus on elderly patients and aims at 
testing the effect of a structured and regular placebo 
device training approach on disease exacerbation rates.
spECIfIC AIMs And hypothEsEs
Our objective is to test the impact of an inhaler technique 
education programme on the risk of exacerbations in 
elderly patients with asthma or COPD.
The main hypothesis is that, among elderly patients with 
asthma or COPD, regular education of inhaler technique 
using a teach-to-goal placebo device-based approach, and 
delivered by family doctors at baseline, 3 and 6 months, 
can reduce the exacerbation risk by 50% after a 1 year 
follow-up, when compared with usual care.
rEsEArCh dEsIgn And MEthodology
study design
Two arms single blinded randomised controlled trial 
with a 1-year follow-up (figure 1). Participants will be 
allocated to each group on a random basis, which is 
defined by a computerised generator and is independent 
of the control of the principal investigator. The alloca-
tion sequence of the 146 participants will be defined 
through a computer generator prior to the start of the 
study. After the generation of this sequence, 146 enve-
lopes will be created, numbered in the appropriate 
order and will contain the result of the allocation. The 
order of the envelopes’ number will define the order of 
participants’ enrolment. The principal investigator will 
not be aware of the information contained within the 
envelopes, thereby maintaining a minimisation rando-
misation process. To ensure the accuracy of the use of 
the envelopes, the documents inside the envelope will 
be signed by the Data Safety Monitoring Board and must 
be returned by the researchers after the allocation of the 
participants.
sample size calculation
Sample size was estimated using the χ² independent group 
proportions approach of STATA Statistical Package, consid-
ering the event proportion in control group of 50% (0.5 
annual rate) as reported in other previous studies21 22 44 
and estimating a reduction of event rate in the interven-
tion group to 25% (0.25 annual rate) as reported in 
similar studies. A 95% CI, with β value (power) of 80%, 
an alpha level of 5% and a ratio of cases/controls of 1:1 
were established. Finally, the sample size was readjusted 
upward, considering an estimated proportion of full 
compliance of the study of 80% (20% losses). The esti-
mated sample size was 116, readjusted to a total of 146 
individuals (73 in each arm).
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Inclusion criteria
Patients with a diagnosis of COPD or asthma, prescribed 
any kind of inhaler device (pressurised Metered Dose 
Inhaler (pMDI) with or without Spacer, Dry Powder Inhaler 
or Soft Mist), aged ≥65 years and being a regular user of 
primary healthcare services (defined as having had at least 
one appointment in the last 2 years with his/her own Family 
Doctor). In order to minimise diagnostic inaccuracy, asthma 
and COPD diagnosis will be reviewed in every participant at 
baseline prior to enrolment and in accordance with GINA 
and GOLD strategies.45 46
Exclusion criteria
Severe or acute illness (such as unstable cardiovascular 
status, unstable angina, recent myocardial infarction 
(within 1 month) or pulmonary embolism, haemoptysis of 
unknown origin, recent pneumothorax (within 1 month), 
recent thoracic, abdominal or eye surgery (within 1 month), 
acute nausea or vomiting, severe respiratory distress, 
dementia).
We will exclude patients who do not need inhaler medica-
tion on a daily basis, since these patients are less susceptible 
to the full impact of the intervention. In addition, these are 
mostly patients with intermittent asthma as well as patients 
with COPD with mild obstruction (GOLD stage I) and tend 
to have a low frequency of disease exacerbations, which 
would hamper our ability to detect a true outcome effect.
predictors/Intervention
Intervention Group: This group will receive a structured 
and regular follow-up plan, with education on inhaler 
technique. Patients will be trained by a Family Doctor (the 
primary investigator) in terms of the inhaler technique 
using placebo devices similar to their own devices. We will 
start by evaluating their baseline technique, and then, a 
teach-to-goal approach will be used with correction of 
identified errors. Then, we will ask patients to demonstrate 
the inhaler technique, and again, committed errors will be 
corrected by demonstration. We will repeat all correct steps 
as many times as needed in order for patients to perform 
them correctly. This intervention will be performed at base-
line, 3 and 6 months. Outcomes will be assessed at base-
line and after 3, 6 and 12 months, since there is dissenting 
evidence about the best timeline to achieve significant 
exacerbation risk reductions.21 30 32 In each visit, and prior 
to the main intervention with the primary investigator, 
assessment of the inhaler technique and application of all 
questionnaires (clinical control, treatment adherence and 
quality of life) will be performed by a secondary blinded 
investigator.
Control Group: This group will receive usual care from 
their own Family doctors, with no specific intervention. 
Each doctor will perform the necessary clinical appoint-
ments according to his/her real life judgement. Besides 
this, this group will have visits at baseline and after 3, 6 
and 12 months to assess secondary outcomes. At each visit, 
assessment of the inhaler technique and application of all 
questionnaires (clinical control, treatment adherence and 
quality of life) will be performed by a secondary blinded 
investigator. At any appointment, if the patient asks for or if 
the clinician decides to teach inhaler technique, that will be 
recorded, since it will be important to analyse and control 
for the true effect size of intervention.
If any adjustments are made in drug classes or device 
types in any participant, this information will be recorded.
outcomes of interest
Primary outcome
Adverse events (continuous, time to event).
Figure 1 Study design diagram.
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For asthma, an event will be defined as increased respi-
ratory clinical symptoms leading the patient to search for 
medical care and resulting in any of the following:
 ► Need for increased inhaled corticosteroid dose of at 
least 4× the regular dose.
 ► Need for increase of short-acting β2 agonists on a daily 
basis.
 ► Need for oral corticosteroids.
 ► Need for oral antibiotics.
 ► Hospitalisation or emergency room (ER) visit with 
increased respiratory clinical symptoms.
For COPD, an event will be defined as increased respira-
tory clinical symptoms prompting the patient to search 
for medical care, and resulting in any of the following:
 ► Need for increase of long-acting β2 agonists on a daily 
basis.
 ► Need for oral corticosteroids.
 ► Need for oral antibiotics.
 ► Hospitalisation or ER visit with increased respiratory 
clinical symptoms.
Respiratory-related mortality and all-cause mortality 
will also be considered an adverse event.
All adverse events and mortality causes will be carefully 
analysed in order to assess their eligibility by two indepen-
dent and external investigators, who will constitute a Data 
Safety Monitoring Board. This will be performed using 
different platforms of clinical records, from the ER of the 
regional reference hospital, from the Primary Healthcare 
facilities (such as PEM for prescribed drugs, SCLINICO 
for clinical records and PDS for ER records) and even by 
asking the participant for additional information. After 
any event, and if necessary for ethical reasons, inhaler 
technique and adherence improvement will be addressed 
by the primary investigator regardless of the participant 
allocation, and in accordance with the recommendation 
of the Data Safety Monitoring Board.
secondary outcomes
 ► Clinical assessment using COPD Assessment Tools 
and modified Medical Research Council for COPD; 
Control of Allergic Rhinitis and Asthma Test47 and 
Asthma Control Test for asthma.48
 ► Quality of Life using St. George’s Respiratory Ques-
tionnaire49 and Clinical COPD Questionnaire50 for 
COPD and Asthma Quality of Life Questionnaire.51
 ► Functional control using Forced Expiratory Volume 
in 1 s (FEV1), forced vital capacity (FVC), peak expira-
tory flow and maximum expiratory flows of 25%–75% 
of FVC (MEF25-75) as a % of predicted value; and 
FEV1/FVC ratio.
 ► Adherence rate using the Brief Medication Question-
naire (this will also evaluate the frequency of using 
the devices).52
 ► Number of errors in inhaler technique (that will be 
standardised to a score up to 100% scale).
(To evaluate inhaler technique performance with 
each device, the Aerosol Drug Management Improve-
ment Team (ADMIT) protocols and guidelines will 
be used,53 evaluating all the recommended steps 
for inhaler use in each one of them (pMDI with or 
without chamber, Qvar Autohaler, Turbohaler, Diskus, 
Aerolizer, Handihaler, Breezhaler, Novolizer, Genuair, 
Twisthaler and Easyhaler). For those devices that do 
not have any protocol from the ADMIT group we 
will use the recommendations from the manufac-
ture`s Summary of Product Characteristics (Soft Mist 
Inhaler, Budesonide from Farmoz, Ellipta, Spiromax 
and Forspiro)).
All questionnaires will be used in validated Portuguese 
versions.47–52 54 55 All participants will perform spirometry 
with bronchodilation test at baseline visit for diagnostic 
confirmation, as well as a baseline spirometry without 
bronchodilation for functional control at subsequent 
visits. A certified provider will perform spirometry.
other variables collected at baseline
 ► Demographics (body mass index, age, sex).
 ► Classification of clinical status, according to:
 – Exacerbation history.
 – Years of diagnosis.
 – Asthma classification/stage according to GINA 
guidelines (clinically as well controlled, partially 
controlled or uncontrolled; and therapeutically as 
in STEP 1, 2, 3, 4 or 5).45
 – COPD stage according to 2017 GOLD guidelines 
(combined assessment stages A, B, C and D; and 
severity of airflow limitation GOLD 1, 2, 3 and 4).46
 ► Social class according to Graffar classification (Portu-
guese version).56
 ► Comorbidities (such as concomitant allergic rhinitis, 
cancer, cardiac heart failure, alcohol or drug abuse, 
current smoking and smoking pack years, diabetes 
mellitus, previous stroke or acute myocardial infarc-
tion, thoracic, abdominal or cerebral aneurysms, 
severe osteoarthrosis in hands and upper limbs).
 ► Depression using Geriatric Depression Scale in 
Portuguese.57
 ► Frailty state in elderly, using a self-reported instru-
ment in Portuguese.58
 ► Cognitive function using Montreal Cognitive Assess-
ment (MOCA) in Portuguese.59
 ► Influenza and pneumococcal vaccination status.
 ► Previous teaching of inhaler technique, specifying the 
education type (placebo device, video, leaflet, multi-
media and so on).
 ► Years of use with current device.
The principal investigator will collect all baseline data 
prior to allocation and randomisation, and this will be 
recorded in a proper form.
statistical analysis
The hypothesis testing approach will be the following:
Null hypothesis
Teaching inhalation technique performance with a 
placebo device approach does not reduce the exacerbation 
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risk in elderly patients with asthma or COPD after a 1-year 
follow-up.
Alternative hypothesis
Teaching inhaler technique performance with a placebo 
device approach reduces the exacerbation risk in elderly 
patients with asthma or COPD after a 1-year follow-up.
Dichotomous predictor




Data will be analysed using the STATA Statistical Package© 
software.
Test statistic for primary outcome
Dichotomous data will be analysed with a two-sample 
proportions χ² test and a COX proportional hazard time-
to-event analysis, and both arms will be compared using 
the measures of association: risk ratio; risk difference; HR 
and number needed to treat analyses.
Test statistic for secondary outcomes
Continuous data will be analysed using parametric tests, 
such as T test for comparison of mean values and dichot-
omous data will be analysed using χ² test. In order to 
test differences between groups in the mean values of 
continuous analysis, mixed effects models for repeated 
measures will be used. For binary outcomes, linear regres-
sion models with group-time interactions will also be 
adapted, and generalised linear models (such as Poisson 
regression) will be applied for exacerbations, as recom-
mended in the literature.60 As an alternative approach, 
generalised estimating equation models will be used to 
handle unmeasured dependence between outcomes.
In case of cohort losses above 20%, comparative anal-
ysis for intention to treat, per-protocol and a multidata 
imputation will be carried out. Missing data will be 
treated as missing completely at random. Subgroup anal-
ysis will be performed according to secondary variables, 
such as diagnosis, age (including stratification into the 
following categories: 65–75, 75–85 and >85 years), sex, 
years of diagnosis, disease classification/stage, comorbid-
ities, educational level, previous teaching of inhaler tech-
nique, device type as well as the specific types of detected 
errors (in order to identify the most critical ones). This 
will be performed using regression models to multivariate 
analyses.
An interim analysis will be performed midway through 
the follow-up, namely at 6 months, defining a significance 
level adjusted by the Bonferroni technique of 0.025.61
study setting
The study will be conducted in a multicentre network 
that will include two or three primary care centres, which 
will be coordinated by a team of experts in the field. All 
of them will be in urban or suburban areas. A Portuguese 
primary care centre usually accounts approximately for 
more than 10 000 patients, and about 30% of them are 
aged above 65 years. Considering an approximate prev-
alence of asthma and COPD of 8% in this population, 
there is a potential target population of almost 250 
patients in each healthcare facility. Recruiting patients at 
more than one site will improve the feasibility, reproduc-
ibility and credibility of the study, but will increase all the 
logistic issues.
All invited participants will have a first contact will 
the primary investigator to confirm the diagnosis and 
all the eligibility criteria, and to carefully explain all the 
study procedures before their inclusion and subsequent 
randomisation. Diagnosis will be confirmed according 
to state of the art and the previously mentioned updated 
guidelines and with spirometry. The number of patients 
screened and deemed ineligible as well as the number of 
patients who are considered eligible but decline partici-
pation will be also recorded.
timeline
 ► Study protocol final version: August 2017.
 ► Ethics consent and scientific academic authorisation: 
December 2017.
 ► Clinical administrative authorisations: first semester 
of 2018.
 ► Multicentre team gathering: first semester of 2018.
 ► Beginning of recruitment: second semester of 2018.
 ► End of recruitment: second semester of 2019.
 ► Data analysis and dissemination: during 2020.
patient and public involvement
No patient or public were involved in the design of this 
protocol, or in the establishment of the intervention and 
the outcome measures. Results from all participants will 
be given to their own family doctors in order to be used if 
deemed necessary to clinical practice.
dIsCussIon
This study is innovative because it includes exclusively 
elderly patients with asthma or COPD, addressing a 
specific placebo device education programme, alone, 
without any other aspects, and it was designed to detect 
a significant reduction on disease exacerbation rate. It is 
expected to detect approximately 55 adverse events, 18 in 
the intervention group and 37 in the control group. In 
addition, it is expected to find a more significant improve-
ment in the intervention group, in all clinical and func-
tional parameters during the follow-up.
This study has some limitations, mainly in selection 
bias due to the risk of missing data and follow-up losses. 
To overcome this problem, different strategies will be 
applied, such as an increase in estimated sample size, 
readjusted for an estimation of 20% losses and sending 
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Another aspect that could bias our study is the 
Hawthorne effect throughout the study (ie, behaviour 
change in participants due to their involvement in the 
study). However, we believe that by establishing a cohort 
time of 1 year, this effect will not be sustained. On the 
other hand, the control group (‘usual care’) will main-
tain their usual care at their own family doctors, who are 
completely free from any influence of the study design. 
For this reason, the control group (‘usual care’) partici-
pants will not receive any intervention from the primary 
investigator. They will only contact with the secondary 
investigator in order to collect endpoints and outcome 
data, and the latter is completely blinded to randomisa-
tion. With this approach, the Hawthorne effect will not 
contaminate the control group and will represent a real 
life usual care. On the other hand, the Data Safety Moni-
toring Board will be composed of two external investiga-
tors, who will, together with the statistician, be blinded 
to the endpoints and outcomes (PROBE setting). Using 
usual care as the comparator arm also brings some limita-
tions to consider, because it is not a perfect comparator 
due to its nature. It is not sufficient for good patient 
outcomes and it is not standardised. This aspect is due, for 
instance, to the fact that patients on usual care can receive 
interventions on inhaler education and self-management 
tools from other uncontrolled sources. To overcome that 
we will retrospectively query patients in this arm and their 
own family doctor for any type of interventions that may 
have been delivered during the study period.
Another possible limitation of our study is that we will 
not use electronic measures of adherence and inhala-
tion techniques. These are a very useful approach to 
monitoring real world adherence to inhaler therapy. 
In fact, these electronic measures overcome the bias 
seen with self-report and other problems observed with 
objective medication checks such as prescription refill 
rates. However, most electronic measures of adherence 
do not measure timing of device activation but rather 
the overall number of activations performed, and, in 
addition, this measure does not mean that medication 
was taken on a regular basis (patients may just activate 
the inhaler several times, prior to handing over the 
device). It is not until recently that a new device has 
been studied, which seems to overcome this problem, 
and which also analyses inhaler technique, but it is not 
widely available—INCA device.62 Nevertheless, these 
devices are expensive and their use could not be imple-
mented in our study. We therefore decided to use the 
adherence questionnaire (BMQ), which is a well-vali-
dated tool in several languages worldwide and also in 
Portuguese.52 Furthermore, it is a very simple and easy 
method to detect non-adherence, which also allows 
separating subdomains of adherence. Thus, it is a good 
tool for assessing adherence in our study involving 
the general population of patients with asthma and 
COPD. Regarding inhalation technique, we decided to 
use regular checklists, since they are the most widely 
method used in other studies, thereby allowing further 
comparisons. They are also easy to use and allow detec-
tion of critical errors in each device.
The standardisation of the protocol intervention is 
another issue to be considered. In order to overcome 
different approaches among different investigators 
from different multicentre sites, a protocol with detailed 
instructions will be created to guide them during the inter-
vention (investigators) and assessment visits (secondary 
investigators). This protocol will explain all the steps and 
procedures for training inhaler technique as well as for 
assessing it, and all the procedures to follow in each visit 
for assessing the outcomes.
Primary investigators will be trained in communica-
tion techniques related to inhaler education of different 
devices and all of them will have a kit of placebo devices 
for use with participants. Such training will allow the stan-
dardisation of all procedures of intervention and it will 
be provided ahead by the coordination team of the study.
Ethics and dissemination
The study protocol has already been analysed by the local 
Ethics Committee of University of Beira Interior, with the 
reference number CE-UBI-Pj-2017–025 and was approved 
on 22 November 2017.
Every participant will sign a written consent form 
(online supplementary appendix I). We decided to 
use ‘usual care’ as the main comparator instead of 
another intervention method, since all interventional 
methods have shown some degree of efficacy in clin-
ically relevant outcomes, as previously mentioned. 
We thus believe that comparing with other education 
methods would minimise the effect detection of our 
teach-to-goal placebo-device intervention. Moreover, 
all of the randomised studies that included mostly 
elderly patients also used ‘usual care’ as a comparator, 
which will be important when comparing them with our 
results. However, we highlight the fact that those studies 
did not use the same age criteria as we are using, since 
they also included non-elderly adult patients in their 
samples. In addition, they did not just focus on inhaler 
teaching, since they provided additional sessions with 
other programme elements, such as self-management 
care. There is, thus, insufficient evidence about the effi-
cacy of inhaler education as an isolated intervention, 
and for that reason, our approach will be novel and will 
significantly contribute towards clarifying those issues.
A Data Safety Monitoring Board will be set up, composed 
of two external investigators with a board expertise in this 
clinical field and in academic and scientific activities, 
to evaluate data obtained throughout the study. Evalu-
ations will occur every 6 months, whatever the number 
of participants enrolled or the follow-up time reached 
at that point. The stop earlier criteria will be defined as 
any moment on follow-up in which the collected data 
show statistically significant differences in the primary 
outcomes. The study may be suspended earlier if suffi-
cient data are obtained for at least 6 months of follow-up 
or if significant evidence of intervention effectiveness is 
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obtained, providing that statistical significance values are 
met by the Bonferroni adaptation.
Invited participants who refuse to participate will be 
evaluated at baseline, according to previously mentioned 
characteristics, in order to compare them with the 
included cohort. They will also be invited to sign a written 
informed consent form that will allow investigators to 
collect such data. The documents used to collect the data 
of the participants will contain only an identification code 
of each participant, in order to protect their identity. The 
code of each participant must be composed of the initials 
of the first two names, followed by the last two digits of the 
National Healthcare Service Number (eg, Name FirstSur-
name SecondSurname, 123456789 ------->code ‘NF89’).
The number of participants considered ineligible will 
be recorded, as well as the number of eligible participants 
who refuse to participate in the study.
The results obtained from this study will be published 
in peer-reviewed journals and presented at scientific 
meetings of primary healthcare and respiratory fields. All 
data recorded during the study will be stored for a period 
of 5 years, in accordance with the Portuguese Clinical 
Research Law, in a safe and proper place in the primary 
investigator`s health centre. After this period, all data that 
contain participants’ codes will be destroyed.
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